Relationship Between Muscle Mass and Muscle Relaxation Time

• Sponsor: Go Eun Bae (Other)
• Overall Status: Completed
• CT.gov ID: NCT02617433
• Collaborator: (none)
• Enrollment: 42
• Location: 1
• Arm: 1
• Duration (Months): 5
• Patients Per Site Per Month: 8.4

Study Details

Study Description

Brief Summary

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. The purpose of this study is to find relationship between muscle mass and muscle relaxation time.

Condition or Disease	Intervention/Treatment	Phase
Anesthesia	Device: Inbody	N/A

Detailed Description

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. Until now, dose of rocuronium has been judged by patient's weight and height. However, height and weight do not represent exact muscle mass. The purpose of this study is to find relationship between muscle mass and muscle relaxation time. Measurement of muscle mass will be obtained using bioelectrical impedence analysis.

Study Design

• Study Type: Interventional
• Actual Enrollment: 42 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and Muscle Relaxation
• Study Start Date: Dec 1, 2015
• Actual Primary Completion Date: May 1, 2016
• Actual Study Completion Date: May 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Inbody Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.	Device: Inbody; Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.

Outcome Measures

Primary Outcome Measures

1. ratio of result of first stimulus(T1) to result of supramaximal stimulation(T0) [two hours]

   T1 and T0 is obtained by train of four which is commonly used neuromuscular monitoring device.

Secondary Outcome Measures

1. completely suppression time of result of first stimulus(T1). [ten minutes]

   T1 is obtained by train of four which is commonly used neuromuscular monitoring device.

Other Outcome Measures

1. Time until reoccurrence of response of first stimulus(T1). [two hours]

   T1 is obtained by train of four which is commonly used neuromuscular monitoring device.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years to 64 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• All patient who undergo general anesthesia.

• Male; weight 70-75kg , height 170-175cm

• Female; weight 53-58kg , height 158-163cm

Exclusion Criteria:

• Liver and kidney disease

• Any types of muscle disorder.

• Metal materials or pacemaker in body

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Korea university anam hospital	Seoul		Korea, Republic of	02841

Sponsors and Collaborators

• Go Eun Bae

Investigators

• Study Director: Seung Zhoo Yoon, MD, PhD, Korea University Anam Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Go Eun Bae, Clinical instructor, Korea University Anam Hospital
• ClinicalTrials.gov Identifier: NCT02617433
• Other Study ID Numbers: Inbody
• First Posted: Dec 1, 2015
• Last Update Posted: May 4, 2016
• Last Verified: May 1, 2016

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided

Study Results

No Results Posted as of May 4, 2016